NCT06669572 2026-02-17
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
University of Chicago
Phase 2 Recruiting
Clinical Trials
14 trialsNCT05273554 2026-01-12
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03564691 2025-10-07
MK-4830-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT06161558 2025-07-16
Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT04976634 2025-04-06
MK-6482-016
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT04193553 2024-06-18
LENVAGIST
Centre Leon Berard
Phase 2 Completed
NCT02640508 2024-05-09
Eribulin and Lenvatinib in Advanced Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT05767684 2023-08-25
Neoantigen Derived DCs as Cancer Treatment
National Health Research Institutes, Taiwan
Phase 1 Recruiting
NCT02501096 2023-07-20
A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT01268293 2023-06-22
A Study of E7080 in Subjects With Solid Tumor
Eisai Inc.
Phase 1 Completed
NCT02915783 2023-01-17
A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
Eisai Inc.
Phase 2 Completed
NCT02686164 2019-08-28
Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors
Eisai Inc.
Phase 1 Completed
NCT00280397 2016-10-07
An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors
Eisai Inc.
Phase 1 Completed
NCT01240408 2015-03-04
E7080 Food Effect Study in Healthy Subjects
Eisai Inc.
Phase 1 Completed